Compositions and Methods for Treating and Preventing Helicobacter Pylori Infections
The present invention provides compositions and methods for treating subject infected with Helicobacter pylori . The invention utilizes natural supplement compositions comprising a blend of essential oils, as well as proton-pump inhibitors and biosurfactants. Advantageously, the present invention can lead to simultaneous improvement of diseases, disorders and conditions caused by H.pylori infection, reduction in the occurrence of H. pylori infections, and reduction in the development of antibiotic-resistant strains of the bacteria.
1 . A supplement composition comprising the following essential oils:
lemongrass oil,
garlic oil,
oregano oil,
Satureja bachtiarica oil, and
ginger oil,
wherein the essential oils are present in sufficient concentrations for the supplement composition to be therapeutically effective.
2 . The composition of claim 1 , further comprising a proton-pump inhibitor (PPI).
3 . The composition of claim 2 , wherein the PPI is omeprazole.
4 . The composition of claim 1 , further comprising a biosurfactant.
5 . The composition of claim 4 , wherein the biosurfactant is a sophorolipid (SLP).
6 . A supplement composition consisting essentially of an essential oil blend comprising lemongrass oil, garlic oil, oregano oil, Satureja bachtiarica oil, and ginger oil,
a PPI, and
a biosurfactant.
7 . The composition of claim 6 , wherein the PPI is omeprazole.
8 . The composition of claim 6 , wherein the biosurfactant is a sophorolipid (SLP).
9 - 10 . (canceled)
11 . A method for treating and/or preventing Helicobacter infection in a subject, wherein the method comprises administering to the subject a therapeutically-effective amount of the composition of claim 1 .
12 . The method of claim 11 , further comprising administering a PPI to the subject.
13 . The method of claim 12 , wherein the PPI is omeprazole.
14 . The method of claim 11 , further comprising administering a biosurfactant to the subject.
15 . The method of claim 14 , wherein the biosurfactant is a purified sophorolipid (SLP).
16 . The method of claim 11 , wherein the supplement composition is administered to the subject orally.
17 . The method of claim 11 , further comprising diagnosing the subject with an Helicobater infection prior to administering the supplement composition.
18 . The method of claim 17 , wherein the infection is caused by one or more of H. bilis, H. bizzozeronii, H. canadensis, H. canis, H. cinaedi, H. fennelliae, H. heilmannii, H. hepaticus, H. pullorum, H. pylori, H. rappini, H. salmonis , and H. suis.
19 . The method of claim 18 , wherein the infection is caused by H. pylori.
20 . The method of claim 11 , further comprising performing follow-up tests on the subject to determine whether, and/or to what extent, the infection has been treated,
21 . The method of claim 11 , used to treat and/or prevent a symptom, disease, disorder or condition of the digestive tract caused by Helicobacter infection, wherein the symptom, disease, disorder or condition is selected from stomach pain, nausea, vomiting, peptic ulcers, stomach cancer, gastritis, GI bleeding, diarrhea, constipation, gas, bloating, food sensitivities, heartburn, acid-reflux, GERD, and indigestion.
22 . (canceled)
23 . The method of claim 11 , used to treat and/or prevent extra-intestinal symptoms associated with a health condition affecting one or more of the cardiovascular system, cerebrovascular system, nervous system, liver, and pancreas.